Stocks TelegraphStocks Telegraph
Stock Ideas

ST Premium

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!

Investor Optimism Drives Up Cassava Sciences (SAVA) Stock

By
Published On January 1, 1970 12:00 AM UTC
Investor Optimism Drives Up Cassava Sciences (SAVA) Stock

Shares of Cassava Sciences, Inc. (NASDAQ: SAVA) experienced a notable increase on Monday, reflecting investor optimism. The company’s stock closed the trading session at $35.08, marking a significant rise of 20.51% on the US stock charts. This uptick coincides with the company’s forthcoming conference call, scheduled for Thursday, August 8th at 8:30 a.m. Eastern Time, where it will outline recent advancements and provide an update on its progress.

Cassava Extended Clinical Trials Duration

Cassava Sciences has announced that it intends to extend its ongoing clinical programs’ open-label extension studies for a maximum of 36 months further. This change to the trial protocol is intended to enable participants who were part of a previous randomized simufilam study for Alzheimer’s disease to keep taking their medicine.

In clinical trials, the information gap between the end of patient treatment and the submission of trial data to regulatory bodies is intended to be filled by the extended open-label research.

The FDA will not be able to review a new application for a simufilam drug until after the limit of 36 months has passed. Furthermore, Cassava plans to incorporate cognitive and plasma biomarker monitoring in the open-label extension trials to collect additional long-term data on the effects of simufilam treatment.

Approximately 89% of participants from Cassava’s ongoing Phase 3 trials have opted to continue with the open-label treatment of simufilam post-blinded trials. Previously, around 100 patients had completed the open-label Phase 3 extension trial without further treatment options. These patients will now have the option, upon approval of the revised protocol modification, to re-enroll in an open-label extension experiment.

Leadership Changes

Additionally, Cassava nominated Richard (Rick) Barry as the company’s chief executive officer and Executive Chairman of the Board. SAVA is seeking a permanent replacement for its current CEO. Mr. Barry takes over for Remi Barbier, who resigned from the board and the corporation as chairman, president, and CEO. Until September 13, 2024, Mr. Barbier will continue to work for the company in a non-executive role with no obligations.

logo

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com

stockstelegraph

Don't have an account?

stockstelegraph

Don't have an account?

stockstelegraph

Already have an account?

stockstelegraph
Smart Screening Tools for Exceptional Returns
stockstelegraph

For just $1, you can unlock ST Grading’s top-rated stocks that consistently beat the market. Our AI-powered Smart Screener finds winning trades in seconds, helping you uncover hidden opportunities before others do.

Ready to Win Big?

Try Now for Just $1!
stockstelegraph